---
title: "LRRK2 Parkinson's Clinical Trials | Parkinson's Pathways"
description: "Recruiting clinical trials for people with LRRK2 gene changes linked to Parkinson's. See enrolling studies, including genetic-specific therapies, and get notified of new trials."
canonical_url: "https://parkinsonspathways.com/trials/pathway/lrrk2"
topic_type: pathway
source: "Parkinson's Pathways"
---
# Clinical Trials for LRRK2 Parkinson's

LRRK2 is one of the most common genes linked to Parkinson's. People who carry certain LRRK2 changes have a higher chance of developing the disease, and a wave of research is now testing treatments aimed specifically at this genetic form.

Some of these trials enroll only people with a confirmed LRRK2 change, while others are studying drugs that block the overactive LRRK2 enzyme. A few also look at family members who carry the gene but do not yet have symptoms.

Below are the recruiting trials we track that involve LRRK2 Parkinson's. Sign up to be emailed when a new one opens.

## 9 recruiting trials

- [Parkinson's Foundation PD GENEration Genetic Registry](https://parkinsonspathways.com/trial/NCT04994015) — Provide Parkinson genetic testing results
- [Phase 1 Study to Evaluate [18F]ACI-15916 as a Potential PET Radioligand for Imaging α-synuclein Deposits in the Brain of Patients With Suspected α-synuclein Pathology Compared With Healthy Volunteers](https://parkinsonspathways.com/trial/NCT06891703) — Detect brain alpha synuclein deposits
- [A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)](https://parkinsonspathways.com/trial/NCT06680830) — Slow early Parkinson disease progression
- [The Chinese Parkinson's Disease With LRRK2 Variants Registry](https://parkinsonspathways.com/trial/NCT03523104) — Map Parkinson progression in carriers
- [Etude Des Facteurs Prédictifs De L'apparition Et De L'évolution De La Maladie De Parkinson](https://parkinsonspathways.com/trial/NCT02305147) — Identify markers predicting Parkinson progression
- [Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease Using [18F]PI-2620: A High-resolution PET Imaging Study Using NeuroEXPLORER (NX PI-2160 in PD)](https://parkinsonspathways.com/trial/NCT07020026) — Brain imaging maps protein clumps
- [An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation](https://parkinsonspathways.com/trial/NCT06732180) — New drug slows Parkinson progression
- [AV133 Longitudinal Imaging Study in Patients With Early and Prodromal Parkinson's Disease](https://parkinsonspathways.com/trial/NCT06456684) — Detect early loss of dopamine
- [The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort](https://parkinsonspathways.com/trial/NCT04477785) — Identify tests predicting Parkinson progression

## Related topics

- [GBA1 Parkinson's](https://parkinsonspathways.com/trials/pathway/gba1)
- [Ambroxol](https://parkinsonspathways.com/trials/drug/ambroxol)

## Related

- [Browse all recruiting trials](https://parkinsonspathways.com/trials)
- [Match yourself to relevant trials](https://parkinsonspathways.com/match)
- [Get the free Monday digest of new recruiting Parkinson's trials](https://parkinsonspathways.com/digest)